Study details
Enrolling now
Mechanistic Studies of Psilocybin in Headache Disorders
Yale University
NCT IDNCT06464367ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
50
Study length
about 1.6 years
Ages
21–70
Locations
1 site in CT
What this study is about
This trial is testing whether psilocybin affects the brain and body in people with migraine. Researchers will measure changes in brain activity, inflammation markers, sleep patterns, and circadian rhythms before and after taking psilocybin or a placebo.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Psilocybin
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug routes
oral
Endpoints
Secondary: Adverse events, Change in IL-6
Body systems
Neurology